Sign Out
Click on icon to see table/diagram/imageEtiologically the onset of hepatic encephalopathy has been related to excess ammonia, short-chain fatty acids and mercaptans. Recent studies have emphasized the importance of other contributory factors involved in severe hepatic impairment: disturbance of the free amino acid pattern in plasma characterized by an increase of L-Phenylalanine, L-Tryptophan, L-Tyrosine and L-Methionine and a decrease of branched-chain amino acids such as L-Leucine, L-Isoleucine and L-Valine.
The disturbance of the free plasma amino acid pattern causes disturbances in the transport of amino acid across the blood-brain barrier, blocks synthesis of false neurotransmitters in the brain, resulting in the disturbance of the overall cerebral amine metabolism. This disturbance of cerebral amine metabolism is suspected to be the major cause of hepatic encephalopathy.
With these findings as background information, Fischer et al developed a special formula of amino acids, containing high concentrations of branched-chain amino acids and low concentrations of L-Phenylalanine, L-Tryptophan and L-Methionine, without L-Tyrosine, to correct the disturbance of the plasma free amino acid pattern. They have conducted experimental and clinical studies of the special formula for the treatment of hepatic encephalopathy and demonstrated that the normalization of the plasma free amino acid pattern is effective in improving hepatic encephalopathy.
AMINOLEBAN is prepared with an amino acid composition identical to that of Fischer's formula. Clinical studies have shown that the injection is effective in correcting plasma amino acid concentrations and the clinical symptoms of hepatic encephalopathy.
pH: Approx 5.9 (mean obtained immediately after manufacture) and 5.5 - 6.5 (specification).
Specific gravity (20°C): 1.025.
Osmolarity: Approx. 768 mOsm/L.
Excipients/Inactive Ingredients: Sodium bisulfite 0.3 g/L is used as a stabilizer.
